Topical polyene antifungals in hematopoietic cell transplant patients: Tolerability and efficacy

Supportive Care in Cancer

Volumn 12, Issue 7, 2004, Pages 517-525

  Epstein, Joel B ^a,b   Truelove, Edmond L ^b   Hanson Huggins, Kimberly ^b   Mancl, Lloyd A ^b   Chen, Alice ^b   Press, Oliver W ^c   Petersdorf, Stephen H ^b   Fritsche, Thomas R ^d   Epstein, Joshua D ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GARGLE; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MALE; MOUTH EXAMINATION; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; TASTE; THRUSH; VOMITING;

EID: 3142721182     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0634-1     Document Type: Article

References (64)

1. Alban J et al (1970) Amphotericin B oral suspension in the treatment of thrush. Curr Ther Res 12:479-484
2. Albougy HA, Naidoo S (2002) A systematic review of the management of oral candidiasis associated with HIV/AIDS. SADJ 57:457-466
3. Alverez ME, Sanchez-Sousa A, Baquero F (1988) A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis. Revista Espanola de Quimio 11:295-315
4. Aviles A (1987) Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Am J Med 82:867-868
5. Barrett AP (1984) Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immunosuppressed patients. Oral Surg Oral Med Oral Pathol 58:148-151
6. Barrett AP (1987) A long-term prospective clinical study of oral complications during conventional chemotherapy for acute leukemia. Oral Surg Oral Med Oral Pathol 63 313-316
7. Bellm L, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Supportive Care Cancer 8:33-39
8. Bellm LA, Epstein JB, Rose-Ped AM, Fu R, Martin PJ, Fuchs HJ (2001) Assessment of various topical oral formulations by bone marrow transplant recipients. Oral Oncology 37:42-49
9. Bergmann OJ (1988) Oral infections and septicemia in immunocompromised patients with hematologic malignancies. J Clin Microbiol 26:2105-109
10. Bodey GP (1988) Topical and systemic antifungal agents. Med Clin NA 72:637-659
11. Boken DJ, Swindells S, Rinaldi MG (1993) Fluconazole-resistant Candida albicans. Clin Infect Dis 17:1018-1021
12. Booogaerts M, Maertens J, van Hoof A, de Bock R, Fillet G, Peetermans M, et al (2001) Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimcrob Chemother 48:97-103
13. Brandell R, Chase SL, Cohn JR (1988) Treatment of oral candidiasis with amphotericin B solution. Clin Pharm 7:70-72
14. Briggs GG, Freeman RK, Yaffe SJ (1994) Drugs in pregnancy and lactation, 4th edn, Williams & Wilkins, Baltimore
15. Ching MS, Raymond K, Bury RW, Mashford ML, Morgan DJ (1983) Absorption of orally administered amphotericin B, lozenges. Brit J Clin Pharmacol 16:106-108
16. Comparison of amphotericin B and nystatin-microbiological studies. Squibb Internal Report, March 6, 1967. Results summarized in NDA 50-341
17. Comparison of amphotericin B and nystatin-microbiological studies. Squibb Internal Report, April 12, 1965. Results summarized in NDA 50-341
18. Davies A, Brailsford S, Broadley K, Beighton D (2002) Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. Palliative Med 16:527-531
19. De Laurenzi A, Matteocci A, Lanti A, Pescador L, Blandino F, Papetti C (1996) Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: a single center experience from 1980-1995. Infection 24:361-366
20. De Vries-Hospers HG, Mulder NG, Sleijfer DT, Van Saene HKF (1982) The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients. Infection 10:71-75
21. DeGregorio MW, Lee WMF, Linker CA, Jacobs RA, Reis CA (1982) Fungal infections in patients with acute leukemia. Am J Med 73:543-548
22. DeGregorio MW, Lee WMF, Ries CA (1982) Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 50:2780-2784
23. Dewsnup DH, Stevens DA (1994) Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Vet Mycol 32:389-392
24. Dick JD, Merz WG Saral R (1980) Incidence of polyene-resistant yeasts recovered from clinical specimens. Anti Ag Chemo 18:158-163
25. Dreizen S, Bodey GP, Valdivieso M (1983) Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg Oral Med Oral Pathol 55:113-120
26. Dreizen S, McCredie KB, Keating MJ, Bodey GP (1982) Oral infections associated with chemotherapy in adults with acute leukemia. Postgrad Med 71:133-146
27. Epstein JB, Gangbar SJ (1987) Oral Mucosal lesions in patients undergoing treatment for leukemia. J Oral Med 43:132-137
28. Epstein JB, Hancock PJ, Nantel S (2003) Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96:154-163
29. Epstein JB, Vickers L, Spinelli J, Reece D (1992) Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 73:682-689
30. Ezdinli EZ, O'Sullivan DD, Wasser LP, Kim U, Stutzman L (1979) Oral amphotericin for candidiasis in patients with hematologic neoplasms: an autopsy study. JAMA 242:258-260
31. Fan Havard P, Capano D, Smith SM, Mangia A, Eng RHK (1991) Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Anti Ag Chemo 35:2302-2305
32. Gotzsche PC, Johansen HK (2002) Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database of Systematic Rev 4:CD002033
33. Greenberg MA, Cohen SG, McKitrick JC, Cassileth PA (1982) The oral flora as a source of septicemia in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 53:32-36
34. Hann IM, Prentice HG, Corringham R, et al (1982) Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1:826-829
35. Holbrook WP, Kippax R (1979) Sensitivity of Candida albicans from patients with chronic oral candidiasis. Postgrad Med J 55:692-694
36. Johansen HK, Gotzsche PC (1999) Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis JAMA 282:1752-1759
37. Korting HC, Ollert M, Georgii A, Froschl M (1988) In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J. Clin Microbio 26:2626-2631
38. Kwon-Chung KJ, Bennett JE (1992) Principles of antifungal therapy. In: Medical mycology, Lea & Febiger, Philadelphia, pp 81-102
39. Lorian V (1996) Antibiotics in laboratory medicine, 4th edn, pp 132-134
40. Main BE, Calman KC, Ferguson MM, et al (1984) The effect of cytotoxic therapy on saliva and oral flora. Oral Surg Oral Med Oral Pathol 58:545-548
41. Menichetti F, Del Favero A, Martin P et al (1994) Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 120:913-918
42. Meunier F (1987) Prevention of mycoses in immunocompromised patients. Rev Infect Dis 9:408-416
43. Meunier-Carpentier F, Cruciani M, Klastersky J (1983) Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur J Cancer Clin Oncol 19:43-48
44. Mirsky HS, Cuttner J (1972) Fungal infection in acute leukemia. Cancer 30:348-352
45. Montes LF (1971) Oral amphotericin B in superficial candidiasis. Clin Med 78:14-17
46. National Committee on Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts (1997) Document M27-A
47. NDA 30-341 for fungizone oral suspension. Filing with FDA by Squibb
48. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K (1994) Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with ADS. Clin Infect Dis 19:684-686
49. Nguyen MT, Weiss PG, Labarre RC, Wallace MR (1994) Oral amphotericin B in the treatment of oral candidiasis due to azole-resistant Candida species (Abstract 287). Abstracts of the 1994 Infectious Disease Society of America, Annual Meeting, Orlando
50. Panzer H, Levenstein M, Barranco A, Green S (1997) Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 24:1204-1207
51. Paterson PJ, McWhinney PH, Potter M, Kibbler CC, Prentice HG (2001) The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients. Brit J Haematol 112:175-180
52. Patton LL, Bonito AJ, Shugars DA (2001) A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of orophayngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:170-179
53. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101-111
54. Pizzuto J, Conte G, Ambriz R, Aviles A, Morales M (1978) Nystatin prophylaxis in leukemia and lymphoma. N Engl J Med 298:279-280
55. Powderly WG, Kobayashi GS, Herzig GP, Medoff G (1988) Amphotericin resistant yeast infection in severely immunocompromised patients. Am J Med 84:826-832
56. Quintiliani R, Owens NJ, Quericia RA, Klinnek JJ, Nightengale CH (1984) Treatment and prevention of oropharyngeal candidiasis. Am J Med 77:44-48
57. Rosenberg-Arksa M, Dekker AW, Branger J, Verhoef J (1991) A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia. J AntiMicrob Chemo 27:369-736
58. Ruhnke M. Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M (1994) Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Micro 32:2092-2098
59. Schimpff SC (1981) Surveillance cultures. J Infect Dis 144:81-84
60. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69:2469-7247
61. Taillandier J, Esnault Y, Alemanni M (2000) A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidosis. Multicentre Study Group. Age Ageing 29:117-123
62. White A, Goetz MG (1994) Azole-resistant Candida albicans: Report of two cases of resistance to fluconazole and review. Clin Infect Dis 19:687-692
63. Williams CJ (1978) Nystatin prophylaxis in leukemia and lymphoma. N Engl J Med 299-313
64. Winston DJ, Gale RP, Meyer DV, Young LS (1979) Infectious complications of human bone marrow transplantation. Medicine 58:1-31